Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Cardiol Therapeutics Inc.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • According to MSCI, the company's ESG score for its industry is poor.
Highlights: Cardiol Therapeutics Inc.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses: Cardiol Therapeutics Inc.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Rating Financials

Cardiol Therapeutics Inc. SectorCanada

Fundamentals

-

Growth

Revenue growth

-

EPS growth

FCF growth

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

More ratings

Rating Valuation

Cardiol Therapeutics Inc. SectorCanada

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Cardiol Therapeutics Inc. SectorCanada

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Cardiol Therapeutics Inc. SectorCanada

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Cardiol Therapeutics Inc. SectorCanada

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
255M - - - -
49.74B
AAA
44.98B -
B
- -
42.52B
AAA
40.78B -
32.89B
A
17.09B - - - -
16.28B
BBB
14.4B
AA
13.48B
AA
Average 27.24B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. CRDL Stock
  4. Ratings Cardiol Therapeutics Inc.